Bacteremia Clinical Trial
— PRO-BACOfficial title:
Spanish Cohort of Bacteriemias 2016: Epidemiology, Clinical Management and Prognostic Factors at Diagnosis.
NCT number | NCT03148769 |
Other study ID # | FIS-AMO-2016-01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2016 |
Est. completion date | May 2019 |
Verified date | May 2019 |
Source | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Bacteremia
The Hypothesis of the study are the followings:
- To demonstrate relevant epidemiologic and clinical changes with potentially impact in
the management and prognosis of the patients with bacteremia.
- Since the diagnosis and management is heterogeneous between centers, we could identify a
scenario to improve.
- To identify quality indicators in the management of bacteremia.
- To demonstrate that some interventions made by Bacteremia Team pose relevant impact in
the prognosis of bacteremia.
Status | Completed |
Enrollment | 5320 |
Est. completion date | May 2019 |
Est. primary completion date | May 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 13 Years and older |
Eligibility |
Inclusion Criteria: - Every episode of bacteremia in patients older than 13 years old, confirmed microbiologically and clinically significant (presence of clinical sepsis data at diagnosis) should be prospectively included on the basis of standard criteria. - Episodes of transient bacteremia may be included. - Drugs will be prescribed in the usual way, according to the conditions established in the authorization. The assignment of a patient to a particular therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice, and the decision to prescribe a particular drug will be clearly dissociated from the decision to include to the patient in the study. Exclusion Criteria: - Bacteremias without clinical relevance |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Punta Europa | Algeciras | Cádiz |
Spain | University General Hospital of Alicante | Alicante | |
Spain | Torrecárdenas Hospital | Almeria | |
Spain | L´ Esperit Sant ( Santa Coloma Granemet) Hospital | Barcelona | |
Spain | University Hospital of Burgos | Burgos | |
Spain | La Linea de la Concepción Hospital | Cádiz | |
Spain | Puerto Real Hospital | Cádiz | |
Spain | University Hospital Puerta del Mar | Cádiz | |
Spain | University Hospital Reina Sofía | Cordoba | |
Spain | Public Health Agency Business Hospital de Poniente. | El Ejido | Almería |
Spain | University Hospital San Cecilio | Granada | |
Spain | University Hospital Virgen de las Nieves | Granada | |
Spain | General Hospital of Granollers | Granollers | Barcelona |
Spain | Ciudad de Jaén Hospital | Jaen | |
Spain | Jerez de la Frontera Hospital | Jerez de la Frontera | Cádiz |
Spain | University Hospital of León | León | |
Spain | University Hospital Arnau de Vilanova | Lleida | |
Spain | University Hospital Carlos Haya ( Málaga) | Málaga | |
Spain | Costa del Sol Hospital | Márbella | Málaga |
Spain | Central University Hospital of Asturias | Oviedo | |
Spain | University Clinic of Navarra | Pamplona | |
Spain | Hospital El Bierzo | Ponferrada | León |
Spain | University Hospital Marqués de Valdecilla | Santander | |
Spain | University Hospital Virgen Macarena | Sevilla | |
Spain | University Virgen de Valme Hospital | Sevilla | |
Spain | University Hospital Mútua de Terrasa | Terrassa | Barcelona |
Spain | Hospital San Juan de la Cruz | Ubeda | Jaen |
Spain | University Hospital of Vigo | Vigo | Pontevedra |
Spain | Universitary Hospital Cruces | Vizcaya |
Lead Sponsor | Collaborator |
---|---|
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Hospital Universitario Virgen Macarena |
Spain,
Al-Hasan MN, Juhn YJ, Bang DW, Yang HJ, Baddour LM. External validation of bloodstream infection mortality risk score in a population-based cohort. Clin Microbiol Infect. 2014 Sep;20(9):886-91. doi: 10.1111/1469-0691.12607. Epub 2014 Mar 26. — View Citation
Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Predictive scoring model of mortality in Gram-negative bloodstream infection. Clin Microbiol Infect. 2013 Oct;19(10):948-54. doi: 10.1111/1469-0691.12085. Epub 2012 Nov 27. — View Citation
Cisneros-Herreros JM, Sánchez-González M, Prados-Blanco MT, Llanos-Rodríguez C, Vigil-Martín E, Soto-Espinosa de los Monteros B, Pachón-Díaza J. [Blood cultures in the emergency department]. Enferm Infecc Microbiol Clin. 2005 Mar;23(3):135-9. Spanish. — View Citation
Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM; Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus d — View Citation
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 20 — View Citation
Gaynes R. Health care--associated bloodstream infections: a change in thinking. Ann Intern Med. 2002 Nov 19;137(10):850-1. — View Citation
Kaye KS. Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia. J Hosp Med. 2012;7 Suppl 1:S13-21. doi: 10.1002/jhm.983. Review. — View Citation
López-Cortés LE, Del Toro MD, Gálvez-Acebal J, Bereciartua-Bastarrica E, Fariñas MC, Sanz-Franco M, Natera C, Corzo JE, Lomas JM, Pasquau J, Del Arco A, Martínez MP, Romero A, Muniain MA, de Cueto M, Pascual A, Rodríguez-Baño J; REIPI/SAB group. Impact of — View Citation
Mosier MJ, Ton-That H. Making the case for de-escalation therapy in ventilator-associated pneumonia once again. Crit Care Med. 2013 Jul;41(7):1810-1. doi: 10.1097/CCM.0b013e31828ce949. — View Citation
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the manage — View Citation
Retamar P, López-Prieto MD, Nátera C, de Cueto M, Nuño E, Herrero M, Fernández-Sánchez F, Muñoz A, Téllez F, Becerril B, García-Tapia A, Carazo I, Moya R, Corzo JE, León L, Muñoz L, Rodríguez-Baño J; Sociedad Andaluza de Enfermedades Infecciosas/Sociedad — View Citation
Retamar P, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, González-Galan V, Del Arco A, Pérez-Santos MJ, Téllez-Pérez F, Becerril-Carral B, Martín-Aspas A, Arroyo A, Pérez-Cortés S, Acosta F, Florez C, León-Ruiz L, Muñoz-Medina L, Rodríguez-Ba — View Citation
Retamar P, Portillo MM, López-Prieto MD, Rodríguez-López F, de Cueto M, García MV, Gómez MJ, Del Arco A, Muñoz A, Sánchez-Porto A, Torres-Tortosa M, Martín-Aspas A, Arroyo A, García-Figueras C, Acosta F, Corzo JE, León-Ruiz L, Escobar-Lara T, Rodríguez-Ba — View Citation
Rodríguez-Baño J, López-Prieto MD, Portillo MM, Retamar P, Natera C, Nuño E, Herrero M, del Arco A, Muñoz A, Téllez F, Torres-Tortosa M, Martín-Aspas A, Arroyo A, Ruiz A, Moya R, Corzo JE, León L, Pérez-López JA; SAEI/SAMPAC Bacteraemia Group. Epidemiolog — View Citation
Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. — View Citation
Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, Asensio A, Calbo E, Cercenado E, Cisneros JM, Cobo J, Delgado O, Garnacho-Montero J, Grau S, Horcajada JP, Hornero A, Murillas-Angoiti J, Oliver A, Padilla B, Pasquau J, Pujol M, Ruiz-Garbajosa P, San Juan — View Citation
Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb — View Citation
* Note: There are 17 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Epidemiology and prognostic factors of bacteremia episodes. | Global incidence and per type of acquisition. Global etiology and per type of acquisition. Frequency of multiresistant and emerging microorganism. Source of bacteremia. Clinical severity of presentation. Clinical failure, mortality at day 7, mortality at day 30, recurrence, length of stay and re-admission at hospital. |
From day 0 to day 30 | |
Secondary | Clinical management of patients with bacteremia during the episode. | Antibiotic therapy used during the episodes (empirical and targeted). Non antibiotic therapy/support therapy used during the episode. Frequency of focus search and adequate control. |
From day 0 to day 30 | |
Secondary | Differences in the management between types of services, wards and hospitals. | Comparison between different services and hospital wards of variables regarding on the management of episodes. | From day 0 to day 30 | |
Secondary | Influence of clinical management in the prognosis. | - Identifying prognostic factors related with mortality, clinical failure and recurrence. | From day 0 to day 30 | |
Secondary | Developing and validating a predictive model for early and late mortality. | - Developing and validating a predictive model for mortality based in prognostic factors related with mortality. | From day 0 to day 30 | |
Secondary | Quality indicators in the management of bacteremia. | - Identifying quality indicators in the management of episodes of bacteremia. | From day 0 to day 30 | |
Secondary | Interventions made by Bacteremia Team. | Frequency and type of interventions made by Bacteremia Teams. Impact of these interventions in the management and prognosis of episodes. |
From day 0 to day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03894046 -
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
|
Phase 3 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|